Delhi High Court vacates ex-parte injunction for wilful suppression by Celagenex Research

A Division Bench of the Delhi High Court, comprising Justice V. Kameswar Rao and Justice Manmeet Pritam Singh Arora, has set aside an ex-parte ad-interim injunction obtained by Celagenex Research (India) Pvt. Ltd. against Nugenesys Pharmaceuticals Pvt. Ltd. and its founder. The Court found that the plaintiff had wilfully suppressed a cease-and-desist notice and a trademark opposition from the plaint to create a false sense of urgency, thereby misleading the Single Judge who granted the injunction.

The Suppressed Details

The dispute concerns nutraceutical products sold under the trademarks 'NUREWIRE' (registered by Celagenex) and 'RewireX' (adopted by Nugenesys). Celagenex had issued a cease-and-desist notice to Nugenesys as early as October 29, 2025 , and later filed an opposition to the 'RewireX' trademark application on January 27, 2026 . Yet, when it approached the High Court in May 2026 seeking an ex-parte injunction, the plaint stated that the plaintiff learned of the infringing mark only in "the first week of May, 2026." The existence of the prior notice and opposition was completely omitted.

The Division Bench noted that the plaint, synopsis, and list of dates all projected a recent cause of action , enabling Celagenex to seek exemption from pre-litigation mediation and from serving advance notice on the defendants. The withheld documents were eventually filed but were "tucked away under a bunch of documents" at serial no. 2 of the index with an obscure description—a practice the Court found insufficient to constitute proper disclosure.

Pattern of Conduct

The Court went a step further, examining three earlier suits filed by the same counsel representing Celagenex. In two other matters—CS(COMM) 328/2022 and CS(COMM) 283/2023—courts had previously returned findings of suppression or concealment in the pleadings. The Division Bench observed: “ If this conduct is overlooked, it would be against all judicial canons. The counsel for the Respondent has literally bound down our hands to write this judgment to ensure that the impugned order stands vacated. ” Invoking the James Bond adage, the Court remarked: “ Once is happenstance. Twice is coincidence. Three times is enemy action. ” It concluded that the repeated non-disclosure was no longer random but a deliberate design to interfere with the judicial process.

The Legal Standard

The judgment reaffirms the fundamental principle that a party seeking an ex-parte equitable remedy must approach the court with uberrima fides —utmost good faith. Quoting extensively from the seminal English case R v. Kensington Income Tax Commissioner (1917) and the Supreme Court’s decision in Oswal Fats and Oils Limited v. Additional Commissioner (2010), the Bench held that suppression of material facts warrants dismissal of the interim application without going into the merits. The Court stated: “ The applicant must state fully and fairly the facts, and the penalty by which the court enforces that obligation is that if it finds out that the facts have not been fully and fairly stated to it, the court will set aside any action which it has taken on the faith of the imperfect statement.

Final Verdict

The Division Bench vacated the ex-parte injunction granted on May 20, 2026, and dismissed the interim application filed by Celagenex Research. It also imposed costs of ₹2,00,000 on the respondent, to be deposited with the Delhi High Court Legal Services Committee within two weeks. The seized products were ordered to be released, with the appellants free to dispose of them. The Court made clear that the products themselves were not sub-standard and that any question of public health or safety would be examined at trial.